Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) vs. capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A ra…
A Reinacher-Schick, M Geißler, U Graeven, W Freier, S Hegewisch-Becker, D Arnold, S Kanzler, G Dietrich, HJ Schmoll, W Schmiegel · Zeitschrift für Gastroenterologie · 2007 · Heft 09
Bibliografische Angaben
Zusammenfassung
Introduction: Bevacizumab (Bev) combined with 5-FU/FA and both, irinotecan or oxaliplatin are standard regimens for mCRC. Recently, a phase III trial has demonstrated that infusional 5-FU can be substituted by capecitabine (cape) when combined with oxaliplatin and Bev whereas conflicting data are available for feasibility and efficacy of cape/irinotecan combinations. Aim: This randomized phase II trial was to compare safety and efficacy of Bev with either CapOx or CapIri in untreated mCRC. Methods: Eligibility criteria: untreated mCRC pts, ECOG PS ≥2, measurable lesion(s), adequate hematologic and organ function…
